Change Password!
Reset Password!
Metformin reduces atrial fibrillation risk and major adverse cardiovascular (CV) events rates in type 2 diabetic patients with pacemakers that could prevent the associated CV complications.
According to a case-control study including type 2 diabetic patients with pacemakers, the use of Metformin therapy could play a pivotal role in reducing the onset of atrial fibrillation (AF) and lowering the risk of major adverse cardiovascular events (MACEs).
Published in ‘Heliyon’ journal, this study investigated 227 patients to assess the outcomes of Metformin on AF, including new-onset AF and the burden of AF. They were stratified into a paroxysmal AF group (80 patients) and a non-AF group (147 patients).
Excitingly, the findings revealed a significant link between Metformin use and a decreased likelihood of new-onset AF in patients without prior AF history. However, no association was found between the AF burden and Metformin in the AF group. This therapy was also linked to a lower frequency of MACEs in both groups, implying that Metformin could offer broader CV protection past its key diabetic management role.
Heliyon
Metformin reduces new-onset atrial fibrillation risk rather than atrial fibrillation burden in type 2 diabetes patients: A case-control study
Chongxia Zhong et al.
Comments (0)